# A POC and Dose-Ranging Study of HTD1801 in PSC Patients

> **NCT03333928** · PHASE2 · COMPLETED · sponsor: **HighTide Biopharma Pty Ltd** · enrollment: 59 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis (PSC)

## Interventions

- **DRUG:** HTD1801
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03333928
- **Lead sponsor:** HighTide Biopharma Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-09
- **Primary completion:** 2020-04-30
- **Final completion:** 2020-08-14
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2025-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03333928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03333928, "A POC and Dose-Ranging Study of HTD1801 in PSC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03333928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*